Apelix’s domestic launch status and latest market price in 2024

Alpelisib (Alpelisib) is a small molecule orally active PI3Kα kinase inhibitor that has attracted much attention because it is specifically designed to treat specific types of breast cancer. The drug has been approved by the US FDA for use in combination with fulvestrant for patients with advanced or metastatic breast cancer with HR+, HER2- and PIK3CA gene mutations. It selectively inhibits PI3Kα and acts exclusively on PIK3CA gene mutations, thereby effectively inhibiting tumor growth and providing better therapeutic effects with relatively minor side effects. Patients are very concerned about the launch status of Apelvis in China and the latest market price. This article will introduce it in detail.

First, regarding the domestic marketing of Apelvis, it is worth noting that although the drug has been available overseas for many years and has won widespread recognition, it has not yet been approved for marketing in China. However, domestic patients can still obtain the drug from overseas markets through legal channels.

In terms of market selling price, the price of Apelix varies depending on the version and region. The original Indian version of Apelvis has attracted much attention due to its high cost performance. The price is about 5,000 yuan per box, and the specifications of each box are 150mg*28 tablets. Compared with original drug versions from other countries, this price is more affordable and reduces the financial burden for patients.

In addition, the Lucius version of the generic version of Apelvis is also available on the Laos market, with the same specifications priced at about more than 2,000 yuan. The quality of this generic drug is guaranteed to a certain extent, and its price is very affordable, providing more choices for patients with limited financial conditions.

For patients, when choosing the version of Apelvis, they should make comprehensive considerations based on their own needs and financial status. At the same time, when purchasing drugs, you should ensure that they come from reliable sources and avoid buying fake and shoddy products. Patients can consult regular overseas medical institutions for help.

In short, although Apelvis has not yet been launched in China in 2024, it still maintains an important position in the global market and provides new treatment options for breast cancer patients. Patients can obtain this drug from overseas markets through legal channels and choose the appropriate version according to their own circumstances.